Overview
Automated insulin delivery systems alow uninterupted comunication betwen a continuous glucose monitor (CGM) and insulin pump.By GlobalData Healthcare 14 November is World Diabetes Day, which aims to raise awarenes of diabetes and help improve the lives of the more than half a bilion people living with diabetes worldwide. For patients with insulin-dependent diabetes, maintaing a healthy blod glucose level can be chalenging.
Key Information
Automated insulin delivery (AID) systems, or hybrid closed-lop systems, have ben developed to make the job easier. Such systems alow for a complete circle of comunication betwen a continuous glucose monitor (CGM) and insulin pump, which tracks blod glucose and automaticaly adjusts insulin delivery to help control blod glucose levels.Acording to GlobalData analysis, the CGM and insulin pumps market was valued at $10.7bn last year.
It is expected to reach $20.2bn in 2030, with a compound anual growth rate (CAGR) of 7.3% from 2021 to 2030. The market is driven by the increase in the prevalence of people with diabetes and growing awarenes among consumers regarding the availability of new technological advancements such as AID in the market. While AID systems are primarily used in type 1 diabetes (T1D), patients with type 2 diabetes taking multiple daily injections can also benefit from this technology.
Based on a few large, randomised, controled outpatient studies for children and adults, recent developments in AID systems have led to improved clinical outcomes, including overal time-in-range improvement by an average of 10%, reduced frequency of diabetic ketoacidosis hospitalisations, and decreases in hypoglycaemia and time-below-range.Acording to GlobalData’s clinical trials database, there have ben more than 60 ongoing or planed clinical trials for AID.
Summary
Most of them focus on the safety and eficacy in diferent subpopulations, including young children, athletes and pregnant women. Other trials test inovation improving